Přejít k obsahu
Merck
  • Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Oncotarget (2015-10-31)
Claire Henry, Estelle Llamosas, Alexandra Knipprath-Meszaros, Andreas Schoetzau, Ellen Obermann, Maya Fuenfschilling, Rosemarie Caduff, Daniel Fink, Neville Hacker, Robyn Ward, Viola Heinzelmann-Schwarz, Caroline Ford
ANOTACE

In recent years, the Wnt signalling pathway has been implicated in epithelial ovarian cancer and its members have potential as diagnostic, prognostic and therapeutic targets. Here we investigated the role of two Wnt receptor tyrosine kinases (RTKs), ROR1 and ROR2, and their putative ligand, Wnt5a, in ovarian cancer. Immunohistochemistry for ROR2 was performed in a large patient cohort, including benign controls, borderline tumours and epithelial ovarian cancer. In addition, siRNA was used to silence ROR1, ROR2 and Wnt5a individually, and together, in two ovarian cancer cell lines, and the effects on cell proliferation, adhesion, migration and invasion were measured. ROR2 expression is significantly increased in ovarian cancer patients compared to patients with benign disease. In vitro assays showed that silencing either receptor inhibits ovarian cancer cell migration and invasion, and concurrently silencing both receptors has an even stronger inhibitory effect on proliferation, migration and invasion. ROR2 expression is increased in epithelial ovarian cancer, and silencing ROR2 and its sister receptor ROR1 has a strong inhibitory effect on the ability of ovarian cancer cells to proliferate, migrate and invade through an extracellular matrix.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
Trioctylphosphine, technical grade, 90%
Sigma-Aldrich
MISSION® esiRNA, targeting human ROR2
Sigma-Aldrich
Trioctylphosphine, 97%
Sigma-Aldrich
MISSION® esiRNA, targeting human RORA
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ror2
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ror1
Sigma-Aldrich
MISSION® esiRNA, targeting human ROR1